The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

Eosinophilic asthma is a more severe subtype of asthma. Treatment options include inhaled and oral corticosteroids, leukotriene modifiers, and biologics. Eosinophilic asthma is a subtype of asthma ...

The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Patients with severe asthma report fatigue, sleep disturbances, physical inactivity, and reduced work productivity as some of ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...

Connect Biopharma (CNTB) announced the online publication of results from the global Phase 2 trial of rademikibart in patients with ...

FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...